Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372110 · ClinicalTrials.gov registry record · Phase 4
Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response
A Phase 4 study of Anxiety, sponsored by University of Texas at Austin.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT02372110: Completed Phase 4 study of Anxiety, sponsored by University of Texas at Austin.
NCT02372110 is a Phase 4 study of Anxiety that has completed, run by University of Texas at Austin. The registered enrollment target is 120 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02372110, a Phase 4 study of Anxiety, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study aims to investigate experimentally anxiety sensitivity and physiologic sensations associated with anxiety using a paradigm combining hydrocortisone, caffeine, and a set of social stress challenges. Following informed consent, participants will be instructed to ingest either 400 milligrams of caffeine (an amount of caffeine roughly equivalent to that in two 8 oz. cups of brewed coffee from Starbucks), and 20 milligrams of hydrocortisone or two placebo capsules via stratified, random assignment. Physiologic and self-reported measures of stress and anxiety will be taken.
Primary Outcome
continuous heart rate monitoring
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HPA, ANS stimulation
Study Locations (1)
Texas
- University of Texas at Austin - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 4 |
What the finished NCT02372110 record still lists
NCT02372110 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02372110 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02372110 about?
NCT02372110 is a clinical study titled "Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response". The proposed study aims to investigate experimentally anxiety sensitivity and physiologic sensations associated with anxiety using a paradigm combining hydrocortisone, caffeine, and a set of social stress challenges. Following informed consent, participants will be instructed to ingest either 400 mi...
What is the current status of trial NCT02372110?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2015-03. Estimated completion is 2015-11.
What conditions does trial NCT02372110 study?
This clinical trial studies the following conditions: Anxiety.
What interventions are being tested in trial NCT02372110?
The interventions under investigation include: Placebo (DRUG), HPA, ANS stimulation (DRUG).
Who is sponsoring clinical trial NCT02372110?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02372110 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02372110's enrollment target sits among peer trials
120 139th of 364 higher than 222 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
RECRUITING · Phase 4
-
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
RECRUITING · Phase 4
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
COMPLETED · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia